Analysts Set Altice USA, Inc. (NYSE:ATUS) PT at $2.30

Altice USA, Inc. (NYSE:ATUS) has received an average rating of “Reduce” from the eleven brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $2.30.

Several equities research analysts have recently weighed in on ATUS shares. Citigroup raised their price objective on Altice USA from $2.50 to $3.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. TD Cowen reduced their target price on Altice USA from $6.00 to $3.50 and set a “buy” rating for the company in a report on Tuesday, November 5th.

Insider Activity at Altice USA

In related news, Director Alt S.A.R.L. Next sold 805,230 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $24.50, for a total transaction of $19,728,135.00. Following the transaction, the director now directly owns 6,651,882 shares of the company’s stock, valued at approximately $162,971,109. The trade was a 10.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 15,299,331 shares of company stock valued at $374,833,610. Company insiders own 52.90% of the company’s stock.

Institutional Investors Weigh In On Altice USA

A number of institutional investors have recently modified their holdings of ATUS. Quadrature Capital Ltd purchased a new stake in shares of Altice USA during the third quarter worth $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Altice USA during the 2nd quarter worth about $25,000. D.A. Davidson & CO. purchased a new stake in shares of Altice USA during the 3rd quarter worth about $32,000. Wolverine Trading LLC acquired a new stake in shares of Altice USA during the 3rd quarter valued at about $39,000. Finally, US Bancorp DE grew its stake in shares of Altice USA by 30.2% in the 3rd quarter. US Bancorp DE now owns 21,530 shares of the company’s stock valued at $53,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 54.85% of the company’s stock.

Altice USA Stock Up 3.4 %

Shares of ATUS stock opened at $2.45 on Wednesday. The stock has a 50-day simple moving average of $2.53 and a 200 day simple moving average of $2.21. The stock has a market capitalization of $1.13 billion, a P/E ratio of -6.62 and a beta of 1.50. Altice USA has a fifty-two week low of $1.52 and a fifty-two week high of $3.19.

Altice USA (NYSE:ATUS) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.13). Altice USA had a negative net margin of 1.85% and a negative return on equity of 1.54%. The business had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.24 billion. During the same quarter last year, the business posted $0.15 EPS. The business’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, sell-side analysts anticipate that Altice USA will post -0.01 earnings per share for the current year.

Altice USA Company Profile

Altice USA, Inc, together with its subsidiaries, provides broadband communications and video services in the United States, Canada, Puerto Rico, and the Virgin Islands. It offers broadband, video, telephony, and mobile services to residential and business customers. The company's video services include delivery of broadcast stations and cable networks; over the top services; video-on-demand, high-definition channels, digital video recorder, and pay-per-view services; and platforms for video programming through mobile applications.